BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1241 related articles for article (PubMed ID: 29567706)

  • 1. Personalized vaccines for cancer immunotherapy.
    Sahin U; Türeci Ö
    Science; 2018 Mar; 359(6382):1355-1360. PubMed ID: 29567706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines.
    Türeci Ö; Vormehr M; Diken M; Kreiter S; Huber C; Sahin U
    Clin Cancer Res; 2016 Apr; 22(8):1885-96. PubMed ID: 27084742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PERSONALIZED NEOANTIGEN VACCINE AGAINST CANCER.
    Pavelić K
    Psychiatr Danub; 2021 May; 33(Suppl 3):S331-S335. PubMed ID: 34010258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
    Aldous AR; Dong JZ
    Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized cancer vaccines: Targeting the cancer mutanome.
    Zhang X; Sharma PK; Peter Goedegebuure S; Gillanders WE
    Vaccine; 2017 Feb; 35(7):1094-1100. PubMed ID: 27449681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
    Mandal R; Chan TA
    Cancer Discov; 2016 Jul; 6(7):703-13. PubMed ID: 27107038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
    Kreiter S; Vormehr M; van de Roemer N; Diken M; Löwer M; Diekmann J; Boegel S; Schrörs B; Vascotto F; Castle JC; Tadmor AD; Schoenberger SP; Huber C; Türeci Ö; Sahin U
    Nature; 2015 Apr; 520(7549):692-6. PubMed ID: 25901682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized cancer neoantigen vaccines come of age.
    Chu Y; Liu Q; Wei J; Liu B
    Theranostics; 2018; 8(15):4238-4246. PubMed ID: 30128050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospect and progress of personalized peptide vaccinations for advanced cancers.
    Sakamoto S; Noguchi M; Yamada A; Itoh K; Sasada T
    Expert Opin Biol Ther; 2016; 16(5):689-98. PubMed ID: 26938083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer neoantigen: Boosting immunotherapy.
    Xu P; Luo H; Kong Y; Lai WF; Cui L; Zhu X
    Biomed Pharmacother; 2020 Nov; 131():110640. PubMed ID: 32836075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoepitopes as cancer immunotherapy targets: key challenges and opportunities.
    Brennick CA; George MM; Corwin WL; Srivastava PK; Ebrahimi-Nik H
    Immunotherapy; 2017 Mar; 9(4):361-371. PubMed ID: 28303769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic cancer vaccines: From initial findings to prospects.
    Song Q; Zhang CD; Wu XH
    Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing neoantigens for personalized cancer immunotherapy.
    Capietto AH; Jhunjhunwala S; Delamarre L
    Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation-Derived Tumor Antigens: Novel Targets in Cancer Immunotherapy.
    Finnigan JP; Rubinsteyn A; Hammerbacher J; Bhardwaj N
    Oncology (Williston Park); 2015 Dec; 29(12):970-2, 974-5. PubMed ID: 26676902
    [No Abstract]   [Full Text] [Related]  

  • 17. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
    Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
    J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.
    Karasaki T; Nagayama K; Kawashima M; Hiyama N; Murayama T; Kuwano H; Nitadori J; Anraku M; Sato M; Miyai M; Hosoi A; Matsushita H; Kikugawa S; Matoba R; Ohara O; Kakimi K; Nakajima J
    J Thorac Oncol; 2016 Mar; 11(3):324-33. PubMed ID: 26752676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines.
    Vormehr M; Türeci Ö; Sahin U
    Annu Rev Med; 2019 Jan; 70():395-407. PubMed ID: 30691374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.